PARIS (dpa-AFX) - French drug maker Sanofi (SNY) announced Tuesday that a pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease or ADPKD did not meet futility criteria
DBV Technologies S.A.: DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors
DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and
Madduri
mbers of its Board of Directors
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. DBV Technologies General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies Board of Directors, in a closed virtual session without the physical presence of shareholders or any other person authorized to attend, at DBV Technologies registered office.
no
ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s
notable
to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.”
In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER2- MBC who were pre-treated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy.